Drug intelligence / Profile preview

4CB-1

Development stage: Unknown
Lead developer: 4C Biomed
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravesical

Overview

4CB-1 (also known as anti-4CB1) is a fully human monoclonal antibody developed by 4C Biomed, with a strategic collaboration with Trigone Pharma. It is being developed for the local administration as an innovative treatment for high-grade non-muscle invasive bladder cancer. The drug functions as an immune checkpoint inhibitor by targeting HVEM (TNFRSF14) and blocking its interaction with BTLA, which leads to the activation of immune cells and enhanced cytotoxicity towards cancer cells.

Other names: anti-HVEM mAbTNFRSF14 inhibitorTNFRSF-14 inhibitorTNFRSF 14 inhibitor

Targets

BTLATMEFF2

Beyond the preview

Go deeper on 4CB-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4CB-1.

Explore the full profile